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Abstract
Right side-out plasma membrane vesicles isolated from HeLa cells exhibited an NADH oxidase activity at their external
 . X  .  .surfaces that was inhibited by the antitumor sulfonylurea, N- 4-methylphenylsulfonyl -N - 4-chlorophenyl urea LY181984 .
 .Intact HeLa cells fresh or frozen also exhibited an NADH oxidase activity at the external cell surface. The inhibition of
 .this activity by LY181984 was enhanced by the addition of epidermal growth factor EGF . The order of addition was
critical. It was necessary that the LY181984 be followed by the EGF. If the EGF was administered first, the response to
w3 xLY181984 was unaffected by EGF. Binding of H LY181984 to HeLa cells also was enhanced by EGF. Growth
experiments with HeLa cells revealed a similar pattern of response to EGF. The EC of growth inhibition of LY18198450
was about 100 mM. However, if the LY181984 was followed by addition of 10 nM EGF, the EC for LY181984 was50
w3 xreduced to about 30 nM which now approximated the previously determined K of H LY181984 binding of 30 nM andd
the EC of 30 nM for inhibition of NADH oxidase activity by LY181984 by isolated vesicles of plasma membranes. The50
 X  .  .tumor-inactive sulfonylurea N- methylphenylsulfonyl-N - phenyl urea LY181985 was ineffective in the inhibition of
NADH oxidation and of growth with HeLa cells either in the presence or absence of EGF.
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1. Introduction
Plasma membranes vesicles of cultured HeLa S
cells bound the tritiated antitumor sulfonylurea
w3 x   . X H LY181984 N- 4-methylphenylsulfonyl -N - 4-
. . chlorophenyl urea with high affinity K of ca. 30d
) Corresponding author. Fax: q1 317 4944007.
. w xnM 1 . Subsequently, a binding protein with one or
more thiols in an active site, was identified and
labeled with radioactive thiol reagents in sulfonylurea
protection experiments. Binding proteins of M ca.r
w x34 kDa were labeled 2 .
The 34 kDa sulfonylurea binding protein was
demonstrated to be correlated with an NADH oxidase
w xactivity 3 . The antitumor sulfonylurea LY181984
inhibited the oxidation of NADH by isolated vesicles
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of plasma membranes from HeLa cells. Both right
side-out and inside-out vesicles of plasma membranes
from HeLa cells oxidized NADH but only the oxida-
tion of NADH with right side-out vesicles was inhib-
w xited by LY181984 4 . These findings suggested that
the oxidation of NADH by plasma membrane vesi-
cles from HeLa cells was inhibited by LY181984 at
w xan external site 4 . The LY181984-inhibited NADH
oxidase was subsequently shown to be released by
HeLa cells and to accumulate in culture media condi-
tioned by growth of HeLa cells. The activity was
isolated from conditioned culture media and shown to
correlate with a ca. 33.5 kDa protein on SDS PAGE
w x5 .
Inhibition of NADH oxidase activity of isolated
plasma membrane vesicles by LY181984 has been
 .shown previously for Harvey ras Hr1.2 trans-
w xformed rat kidney cells 6 and a cloned line of
w xadenocarcinoma cells designated GC rC 6 devel-3 1
oped by Dr. Peter Houghton, St. Jude Children’s
w xHospital, Memphis, TN 7 . For both the sulfony-
lurea-sensitive rat kidney and adenocarcinoma cell
lines, the inhibition by LY181984 of NADH oxida-
tion by isolated plasma membrane vesicles was aug-
w xmented by the addition of EGF 6 .
In this report, we demonstrate a similar augmenta-
tion of the inhibition of NADH oxidation by EGF
with intact HeLa cells. Also augmented by EGF
addition was the ability of LY181984 to inhibit
growth. The growth inhibition by LY181984 was
markedly augmented by EGF and the EC for50
LY181984 in the absence of EGF of 100 mM was
lowered to 30 nM in the presence of EGF. We
reported previously that the inhibition by LY181984
augmented by EGF was observed only if the
LY181984 was followed by EGF but not if the
w xadditions were made in the reverse order 6 . A
similar dependence on order of addition was ob-
served in the present study.
The augmentation of inhibition of NADH oxida-
tion by EGF addition may have relevance to both an
understanding of conditions favorable to growth inhi-
bition by sulfonylureas and possibly, as well, to an
understanding of conditions favorable to therapeutic
intervention by sulfonylureas in cancer control. An
interaction between EGF and oxidation of NADH by
plasma membranes of rat liver was reported previ-
w xously 8 .
2. Materials and methods
2.1. Growth of cells
HeLa S cells were grown on Minimal Essential
 .  .Medium S-MEM Joklik modified with glutamine
 .  .244 mgrl and phosphate 1.3 grl Na HPO and2 4
without CaCl plus 5% donor horse serum. Gen-2
 . tamycin sulfate 50 mgrl and sodium bicarbonate 2
.grl were added. Cells were collected by centrifuga-
tion for 6 to 15 min at 1000 to 3000 rpm e.g. 6 min
.at 3000 rpm or 15 min at 1000 rpm .
 .Attached HeLa cells ATCC CCL2 , were grown
in 150 cm flasks in Minimal Essential Medium
 .Gibco , pH 7.4, at 378C with 10% bovine calf serum
 .heat-inactivated , plus 50 mgrl gentamycin sulfate
 .Sigma . Cells were trypsinized with Sigma IX trypsin
for 1 to 2 min, washed with phosphate-buffered
 . w xsaline PBS 9 , and resuspended in 50 mM Tris-Mes
 .buffer pH 7.0 for assay. Cell survival was deter-
mined by Eosin Y exclusion.
Table 1
Response of the oxidation of NADH by intact HeLa cells to the
 .antitumor sulfonylurea LY181984 10 mM in DMSO or DMSO
alone and 10 nM EGF
Treatment and order NADH oxidase activity
6 .of addition nmolrmin per 10 cells
a bFresh Frozen
CellsqNADHqKCN 0.30"0.040 0.20"0.009
qLY181984 0.30"0.036 0.18"0.016
qLY181984qEGF 0.18"0.030 0.13"0.012
CellsqNADHqKCN 0.33"0.030 0.20"0.018
qEGF 0.36"0.045 0.21"0.023
qEGFqLY181984 0.33"0.030 0.19"0.029
CellsqNADHqKCN 0.32"0.051 0.20"0.019
qDMSO 0.30"0.030 0.18"0.031
qDMSOqEGF 0.30"0.045 0.19"0.011
CellsqNADHqKCN 0.32"0.040 0.19"0.016
qEGF 0.36"0.045 0.20"0.016
qEGFqDMSO – 0.18"0.015
Components were added in the order given. Each addition was
separated by approximately 10 min. The final DMSO concentra-
tion was 0.1%
a Average of 6 experiments"S.D.
b Average of 10 experiments"S.D.
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Fig. 1. Inhibition of NADH oxidase activity of intact HeLa cells
by increasing concentrations of LY181984 in the absence solid
.  .symbols and presence open symbols, dashed line of 10 nM
 . epidermal growth factor EGF . The LY181984 in DMSO final
.concentration of DMSO of 0.1% was added first and a rate of
NADH oxidation was determined over 10 min. The EGF was
then added and the new rate of NADH oxidation was determined
over 10 min. Results are based on averages of three experiments
"standard deviations among experiments.
2.2. Spectrophotometric assay
NADH oxidase activity was determined as the
disappearance of NADH measured at 340 nm with
430 nm as reference using an SLM Aminco DW-2000
spectrophotometer in the dual wavelength mode of
operation with continuous recording over 5- or 10-min
intervals once steady-state rates were attained. The
reaction mixture contained 50 mM Tris-Mes buffer
 .pH 7.0 , 2 mM KCN to inhibit any potential mito-
chondrial oxidase activity, and 150 mM NADH in a
total volume of 2.5 ml. Assay was at 378C with
constant stirring. Cells were assayed fresh or stored
 .frozen y708C as a pellet. The final density in the
assay was 1 to 3=106 cellsr2.5 ml assay. Cell
numbers were determined using a hemocytometer. A
millimolar extinction coefficient of 6.22 was used to
determine NADH disappearance.
Proteins were determined by the bicinchoninic acid
 . w xBCA assay 10 using bovine serum albumin as
standard.
2.3. Growth measurement
Cells were treated in 35=10 mm plastic dishes in
2.5 ml culture medium. Sulfonylureas were dissolved
in DMSO and added in 2.5 ml of DMSO to yield a
final DMSO concentration of 0.1%. EGF was added
in 1000-fold concentrated aqueous solution 15 min
later. Controls received 2.5 ml of DMSO. Growth
was determined from cell numbers estimated after 24,
48, 72 and 96 h of treatment.
3. Results
 .Intact HeLa cells oxidized NADH Table 1 . In
contrast to isolated vesicles of plasma membranes,
Fig. 2. Inhibition of NADH oxidase activity of intact HeLa cells
by increasing concentrations of LY181985 in the absence solid
.  .symbols and presence open symbols, dashed line of 10 nM
 . epidermal growth factor EGF . The LY181985 in DMSO final
.concentration of 0.1% was added first and a rate of NADH
oxidation was determined over 10 min. The EGF was then added
and the new rate of NADH oxidation was determined over 10
min. Results are based on averages of three experiments"S.D.
among experiments.
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Fig. 3. Inhibition of NADH oxidase activity of intact HeLa cells
 .by increasing concentrations of epidermal growth factor EGF in
 . the absence solid symbols and in the presence open symbols,
.dashed line of 10 mM LY181984. To determine NADH oxida-
tion in the absence of LY181984, DMSO final concentration of
.0.1% was added and the rate of NADH oxidation was deter-
 .mined over 10 min. EGF 10 nM was then added and the
response to EGF was determined over 10 min of incubation. To
determine the effect of EGF on inhibition of NADH oxidation by
LY181984, the cells were first incubated with 10 mM LY181984
 .in DMSO final DMSO concentration of 0.1% as described for
Fig. 1 and the rate of NADH oxidation was determined over 10
min. Results are averages of three experiments"S.D. among
experiments.
this oxidation was little affected by the antitumor
sulfonylurea LY181984. However, sulfonylurea sen-
sitivity could be induced if the sulfonylurea addition
was followed by 10 nM EGF. EGF alone had no
effect or was stimulatory. If the LY181984 and the
EGF were reversed in the order of addition with the
EGF being added first, the result was the same as in
 .the absence of EGF Table 1 .
With intact HeLa cells treated first with varying
concentrations of LY181984 and then followed by 10
nM EGF, the inhibition of NADH oxidation by the
plasma membrane vesicles to LY181984 was half
 .maximal at about 30 nM LY181984 Fig. 1 . The
antitumor inactive sulfonylurea LY181985 which dif-
fers from LY181984 by a single chlorine on the B
ring, was without effect on NADH oxidation either in
 .the presence or in the absence of EGF Fig. 2 . The
concentration optimum for EGF was determined to
be 1 nM or greater for the inhibition of oxidation of
 .NADH by added LY181984 at 10 mM Fig. 3 .
In growth studies, following the addition of
LY181984 by addition of EGF resulted in greatly
 .enhanced growth inhibition Fig. 4 . With 10 nM
EGF added 15 min following the addition of
LY181984, the EC for LY181984 was -1 mM50
 .Fig. 4 . However, in the absence of EGF, the EC50
 .was )100 mM Fig. 4 . The antitumor inactive
LY181985 was without effect on growth either in the
 .presence or absence of 10 nM EGF Fig. 4 . In a
separate experiment, growth was redetermined as a
function of sulfonylurea concentration comparing
LY181984 and LY181985, both followed by 10 nM
 .EGF to more precisely determine the EC Fig. 5 .50
The LY181985, again, was largely ineffective.
Fig. 4. Growth over 72 h of culture of HeLa cells inhibited by the
antitumor-active sulfonylurea LY181984 added in DMSO solu-
 . tion final DMSO concentration of 0.1% in the absence solid
.  .symbols or presence open symbols, dashed line of 10 nM EGF.
The chemically related antitumor-inactive LY181985 added in
 .DMSO final concentration of DMSO of 0.1% was ineffective in
 .the inhibition of growth either in the absence solid triangles or
 .presence open triangles, dashed line of 10 nM EGF. With
LY181984, the concentration required for 50% inhibition of
growth was shifted several log orders to lower concentrations by
 .the presence of 10 nM EGF see also Fig. 5 . Results are
averages of three experiments"S.D. among experiments.
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 .Fig. 5. Effect of 10 nM epidermal growth factor EGF on the
growth response of HeLa cells to the antitumor-active sulfony-
 .lurea LY181984 solid symbols and to the antitumor-inactive
 .sulfonylurea LY181985 open symbols, dashed curve over 72 h
of culture. The concentration of the antitumor-active LY181984
required for 50% inhibition of growth in the presence of 10 mM
EGF was about 30 nM compared to approximately 100 mM in
 .the absence of 10 nM EGF Fig. 4 . Results are averages from
two experiments.
LY181984 inhibited growth with an EC of ca. 3050
nM LY181984 when followed by 10 nM EGF.
w3 xBinding of H LY181984 to right side-out plasma
membrane vesicles in the presence of 10 nM EGF
was 10"1 pmolrmg membrane protein in three
independent determinations compared to 4 " 0.8
pmolrmg membrane protein in its absence. These
values are comparable to values reported previously
based on estimates using equilibrium dialysis meth-
w xods 1 .
4. Discussion
An NADH oxidase activity of the mammalian
plasma membrane was first described for rat liver
where the activity was found to be growth factor- and
hormone-stimulated as well as resistant to cyanide
w x8,11 . The growth factor- and hormone-responsive-
ness of the plasma membrane NADH oxidase was
lost or at least greatly reduced upon transformation
w x12,13 although a low level of response to EGF,
approximately 25% of that of rat liver, was retained
by plasma membranes prepared from rat hepatomas
w x13 .
The inhibition of plasma membrane NADH oxi-
dase activity by the active antitumor sulfonylurea
appeared to be unique to plasma membrane vesicles
of cancer cells and was not given by plasma mem-
branes from rat liver, normal rat kidney cells or
human colon cancer lines unresponsive to sulfony-
w xlureas 3,6 . However, LY181984 inhibition could be
enhanced by adding 10 nM EGF in series following
w xthe LY181984 6 . In contrast to the transformed rat
kidney plasma membranes and the sulfonylurea-re-
w xsponsive human colon lines 6 , the NADH oxidase
activity of vesicles of plasma membranes isolated
from HeLa cells was strongly inhibited even without
the subsequent EGF addition. However a major dis-
crepancy was that with HeLa cells grown in culture,
the dose-response of LY181984 inhibition of the
w xNADH oxidase yielded an EC of about 30 nM 350
whereas the EC of growth inhibition was approxi-50
w xmately 100 mM 14 . However, if the addition of
LY181984 to the cell cultures was followed by EGF,
the growth was much more dramatically reduced in
response to the LY181984. The combination of
LY181984 and EGF yielded an EC for LY18198450
of about 30 nM, comparable for that of inhibition of
oxidation of NADH by LY181984 with isolated
plasma membrane vesicles.
In contrast to that of isolated plasma membrane
vesicles, the response of the NADH oxidase activity
of intact HeLa cells corresponded more closely to the
growth response of HeLa cells grown in culture. With
intact cells of HeLa the NADH oxidase activity was
little affected by LY181984 unless followed by EGF.
When followed by EGF, the dose response of
LY181984 inhibition of NADH oxidase activity of
intact HeLa cells paralleled closely that of growth
inhibition with an EC of about 30 nM.50
The antitumor inactive sulfonylurea LY181985
differs from LY181984 by the absence of a single
chlorine on the B ring and in this study served as a
specificity control. LY181985 was without effect on
NADH oxidation nor did it inhibit growth either in
the absence or in the presence of EGF. Therefore the
response to EGF was observed only with the antitu-
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mor-active LY181984 and not with the inactive
LY181985.
The basis for the EGF stimulation of sulfonylurea
inhibition of NADH oxidation observed with HeLa
cells, and plasma membranes from ras transformed
w xNRK cells 6 and a sulfonylurea-responsive human
w xcolon cancer cell line 6 is not known. Also un-
known is why the EGF addition is important for
LY181984 inhibition in whole cells of HeLa, even
those stored frozen, but not with isolated plasma
membrane vesicles either stored frozen or assayed
w xfresh 5 . The results are important, however, in that
the EC for inhibition of NADH oxidation and for50
inhibition of growth with intact HeLa cells correlated
much more closely when the LY181984 addition was
followed by EGF. A puzzling characteristic of the
antitumor sulfonylureas, e.g., Sulofenur, has been
their ability to effectively kill human colon xenografts
in the intact animal but to be less effective in killing
xenograft cells or other cell lines when grown in
w xculture 15–17 . While sulfonylurea-growth factor in-
teractions in situ may not contribute to these differ-
ences, through the administration of LY181984 and
EGF in series, it is now possible to inhibit the growth
of cultured cells by nanomolar concentrations of
LY181984 comparable to concentrations effective in
situ.
That the LY181984 and the EGF must be adminis-
tered in the order where the EGF follows the
LY181984 would be consistent with the suggestion
that the EGF may somehow facilitate binding of
LY181984. That the plasma membrane NADH oxi-
dase responds to EGF with vesicles from rat liver, for
example, suggested that the oxidase protein may
normally be coupled in the membrane to growth
factor responses. This coupling, however, appeared to
w xbe lost in transformation 12,13 . One possibility to
explain the EGF-sulfonylurea interaction is that the
presence of the sulfonylurea restores the coupling
between growth factor response and NADH oxidase
in plasma membranes of the transformed HeLa cells.
The result is a response to EGF, but not one of
stimulation of NADH oxidase activity and growth as
in the normal cell, but one of an enhanced inhibitory
response to the sulfonylurea.
The inhibition of growth of HeLa cells by
LY181984 or the combination of LY181984 and
EGF may be related in part to a failure of the
inhibited cells to enlarge normally following cytoki-
w xnesis 14 . As a result, further division is slowed or
prevented. Once cells divide, the daughter cells must
enlarge to reach a certain minimal size to re-enter
w xmitosis 18 . The small cells resulting from treatment
with LY181984 subsequently fail to enter mitosis
and, after a few days, begin to exhibit characteristics
w xof apoptotic cell death 14 . Why cells fail to enlarge
normally may relate to a more general function of the
NADH oxidase protein in the catalysis of protein
disulfide-thiol interchange potentially related to
w xmechanisms of physical membrane displacement 19 .
w xBoth protein and drug site appear to be external 20
and absent from normal cells. Because the drug site is
external, drugs directed to the responsive cell surface
NADH oxidase need not enter the cells to be effec-
tive. These considerations combine to suggest the
NADH oxidase protein of the cancer cell surface to
offer unusual opportunities as a target for develop-
ment of cancer cell-specific antitumor agents.
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